logo

Entasis Therapeutics Holdings Inc (ETTX)



Trade ETTX now with
  Date
  Headline
6/27/2019 8:21:01 AM Entasis Therapeutics Announces Multiple Presentations Of Innovative Programs
6/24/2019 8:08:57 AM Entasis Therapeutics Appoints David Meek As Chairman Of Board
6/13/2019 8:08:49 AM Entasis Therapeutics Reports Initial Preliminary Results From ETX0282 Trial
4/4/2019 8:12:44 AM Entasis Therapeutics Begins Global Phase 3 Pivotal Trial Of ETX2514SUL For Carbapenem-Resistant Acinetobacter Infections
4/2/2019 7:44:35 AM Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) FY19 Estimate To -2.75 From -3.34
4/2/2019 7:44:18 AM Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) Q4 19 Estimate To -0.63 From -0.81
4/2/2019 7:44:06 AM Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) Q3 19 Estimate To -0.59 From -0.76
4/2/2019 7:43:53 AM Wedbush Is Raising Entasis Therapeutics Holdings Inc (ETTX) Q2 19 Estimate To -0.80 From -0.92
4/2/2019 7:43:33 AM Wedbush Is Raising Entasis Therapeutics Holdings Inc (ETTX) Q1 19 Estimate To -0.74 From -0.85
3/29/2019 7:41:20 AM Entasis Therapeutics FY Net Loss $33.0 Mln Vs Loss Of $29.9 Mln Last Year
2/5/2019 8:07:45 AM Entasis Therapeutics Gets Positive Feedback From FDA End-of-Phase 2 Meeting For ETX2514SUL; Signs Deal With BioMérieux
11/14/2018 8:20:09 AM Entasis Therapeutics Q3 Net Loss $8.5 Mln; Says On-track To Begin Two Phase 3 Clinical Trials In 2019
10/22/2018 6:23:46 AM Wedbush Initiates Entasis Therapeutics Holdings Inc (ETTX) At Outperform With $19 Price Target